UroGen Pharma Ltd.
NASDAQ:URGN
Overview | Financials
| Company Name | UroGen Pharma Ltd. |
| Symbol | URGN |
| Currency | USD |
| Price | 21.42 |
| Market Cap | 990,977,022 |
| Dividend Yield | 0% |
| 52-week-range | 3.42 - 21.71 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Ms. Elizabeth A. Barrett |
| Website | https://www.urogen.com |
An error occurred while fetching data.
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD





